JP2003528139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528139A5 JP2003528139A5 JP2001570257A JP2001570257A JP2003528139A5 JP 2003528139 A5 JP2003528139 A5 JP 2003528139A5 JP 2001570257 A JP2001570257 A JP 2001570257A JP 2001570257 A JP2001570257 A JP 2001570257A JP 2003528139 A5 JP2003528139 A5 JP 2003528139A5
- Authority
- JP
- Japan
- Prior art keywords
- xanthophyll
- expression
- astaxanthin
- animal
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 235000013793 astaxanthin Nutrition 0.000 description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 4
- 229940022405 astaxanthin Drugs 0.000 description 4
- 239000001168 astaxanthin Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 4
- 229960005375 lutein Drugs 0.000 description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 4
- 235000008210 xanthophylls Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229940124788 therapeutic inhibitor Drugs 0.000 description 2
- 241000168525 Haematococcus Species 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001071-0 | 2000-03-27 | ||
| SE0001071A SE0001071D0 (sv) | 2000-03-27 | 2000-03-27 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
| PCT/SE2001/000600 WO2001072296A1 (en) | 2000-03-27 | 2001-03-21 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528139A JP2003528139A (ja) | 2003-09-24 |
| JP2003528139A5 true JP2003528139A5 (cg-RX-API-DMAC7.html) | 2008-05-15 |
Family
ID=20279020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570257A Pending JP2003528139A (ja) | 2000-03-27 | 2001-03-21 | 炎症性サイトカインおよびケモカインの発現を阻害する方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267857B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003528139A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE353639T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2001242965A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2405479C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60126591D1 (cg-RX-API-DMAC7.html) |
| SE (1) | SE0001071D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001072296A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003048202A2 (en) * | 2001-12-03 | 2003-06-12 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
| EP2653157B1 (en) * | 2004-02-04 | 2016-08-03 | Fuji Chemical Industry Co., Ltd. | Astaxanthin for improving muscle atrophy |
| JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
| JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
| JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
| US7805004B2 (en) * | 2007-02-28 | 2010-09-28 | Microsoft Corporation | Radical set determination for HMM based east asian character recognition |
| WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05155736A (ja) * | 1991-12-10 | 1993-06-22 | Nakano Seiyaku Kk | 化粧料 |
| JPH0799924A (ja) * | 1993-09-30 | 1995-04-18 | Nippon Suisan Kaisha Ltd | アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法 |
| JPH07300421A (ja) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | 抗炎症剤 |
| US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
| US5886053A (en) * | 1995-02-03 | 1999-03-23 | Basf Aktiengesellschaft | Use of carotenoids for producing drugs for the treatment of dermatoses |
| JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
| JPH09143063A (ja) * | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
| SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
| EP0984915A4 (en) * | 1997-04-04 | 2002-11-27 | Henkel Corp | LUTEINE ESTERS WITH HIGH BIOAVAILABILITY |
| SE512531C2 (sv) * | 1997-09-04 | 2000-03-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur |
-
2000
- 2000-03-27 SE SE0001071A patent/SE0001071D0/xx unknown
-
2001
- 2001-03-21 AU AU2001242965A patent/AU2001242965A1/en not_active Abandoned
- 2001-03-21 AT AT01916022T patent/ATE353639T1/de not_active IP Right Cessation
- 2001-03-21 CA CA2405479A patent/CA2405479C/en not_active Expired - Fee Related
- 2001-03-21 DE DE60126591T patent/DE60126591D1/de not_active Expired - Fee Related
- 2001-03-21 EP EP01916022A patent/EP1267857B1/en not_active Expired - Lifetime
- 2001-03-21 JP JP2001570257A patent/JP2003528139A/ja active Pending
- 2001-03-21 WO PCT/SE2001/000600 patent/WO2001072296A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60134855D1 (de) | Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen | |
| ITMI20020399A1 (it) | Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici | |
| NO20056223L (no) | Preparat til behandling av infeksjon hos kveg og svin | |
| CY1118519T1 (el) | Συνθεση τετρακυκλινων και αναλογων αυτων | |
| ATE241352T1 (de) | Omega-3-fettsäurehaltige zubereitung aus mikroorganismen als prophylaktikum bzw. therapeutikum gegen kokzidiose bei tieren | |
| PE20040751A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO | |
| DE60331583D1 (de) | Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen | |
| CY1110061T1 (el) | Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης | |
| AR098251A2 (es) | Uso de aivlosin o de una sal de adición ácida del mismo farmacológicamente aceptada para la preparación de un medicamento de uso veterinario, un alimento para aves de corral o cerdos, una composición recubierta estable para ser agregada a dicho alimento y un medicamento de uso veterinario | |
| PT1401415E (pt) | Utilizacao de derivados de n-fenil-2-pirimidino-amina para o tratamento de doencas inflamatorias | |
| DK1401413T3 (da) | Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme | |
| WO2003004007A3 (en) | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) | |
| CO5221025A1 (es) | 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos | |
| WO2003002105A3 (en) | Use of tyrosine kinase inhibitors for treating bone loss | |
| ATE297223T1 (de) | Teilchenförmige vitaminzubereitung | |
| NO975191L (no) | Diaromatiske propynyl- eller dienylforbindelser | |
| ATE401078T1 (de) | Die verwendung von c-kithemmern zur förderung des haarwuchses | |
| WO2002064558A3 (en) | Oxazole derivatives, their preparation and their use as cytokine inhibitors | |
| AR042677A1 (es) | Composiciones y metodos de cuidado oral | |
| SE9704590D0 (sv) | Method of increasing the production and improving the quality of semen | |
| CR7515A (es) | Composicion veterinaria inyectable para animales pequenos | |
| SE0001071D0 (sv) | Method of inhibiting the expression of inflammatory cytokines and chemokines | |
| WO2001080891A8 (en) | Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same | |
| AR000555A1 (es) | Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo | |
| BRPI0417692A (pt) | uso de uma composição, método de redução dos efeitos do estresse mediado psicologicamente na pele de um ser humano ou animal, composição, suplemento nutritivo, composição cosmética, e, método para identificar um composto capaz de reduzir os efeitos e método de produção de uma composição para a redução dos efeitos, do estresse mediado psicologicamente sobre a pele de um ser humano ou animal |